![]() The neutralisation of CD147, either using a blocking antibody or mRNA silencing, reduced ERK1/2 activation, and rescued PC function in the presence of the S protein. Next, adopting a blocking strategy against the S protein receptors angiotensin-converting enzyme 2 (ACE2) and CD147, we discovered that the S protein stimulates the phosphorylation/activation of the extracellular signal-regulated kinase 1/2 (ERK1/2) through the CD147 receptor, but not ACE2, in PCs. Exposure to the recombinant S protein alone elicited signalling and functional alterations, including: (1) increased migration, (2) reduced ability to support endothelial cell (EC) network formation on Matrigel, (3) secretion of pro-inflammatory molecules typically involved in the cytokine storm, and (4) production of pro-apoptotic factors causing EC death. Here we newly show that the in vitro exposure of primary human cardiac PCs to the SARS-CoV-2 wildtype strain or the α and δ variants caused rare infection events. We tested this hypothesis in pericytes (PCs), which are reportedly reduced in the heart of patients with severe coronavirus disease-2019 (COVID-19). Additionally, the SARS-CoV-2 Spike (S) protein may act as a ligand to induce non-infective cellular stress. The capacity of SARS-CoV-2 to infect vascular cells is still debated. Raszek details the ramifications of the spike proteins entering the cell nucleus.The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes a broad range of clinical responses including prominent microvascular damage. Spike protein inside nucleus enhancing DNA damage? – COVID-19 mRNA vacci… via Diana C November 14, 2021 ![]() (Thanks to ĬOVID-19 mRNA vaccines update 18 - Dr Mikolaj Raszek, Phd, Merogenomics Mikolaj Raszek, PHD on the Swedish paper describing the spike protein entering the nucleus of human cells and what it does there. Raszek made a video discussing the implications of spike proteins entering the nucleus of human cells and inhibiting DNA repair.ĭr. came into existence to provide greater awareness and education about the benefits (and limitations) of genome sequencing.ĭr. Raszek decided to start a business that would provide access to genome sequencing to the general public. The benefits that genomic sequencing could offer became clear, and in 2014 Dr. Raszek found employment in Edmonton at Livestock Gentec, a young company dedicated to exploring the commercial benefits of genomic research in the Canadian livestock industry. Continued interest in microbial genomics exposed him to the still novel but burgeoning field of genomic medicine based on human DNA sequencing, and he decided to continue his career in this area of science. Raszek moved to Germany in 2012 to work at the University of Leipzig. ![]() Raszek became excited by combinatorial biosynthesis and its application to genomics.Īfter defending his PhD dissertation, Dr. Mikolaj Raszek holds a degree in Honours Genetics as well as a doctorate degree in Biochemistry, both obtained at the University of Alberta in Edmonton. Mikolaj Raszek in 2015, who currently manages the corporation. Merogenomics Inc., based in Edmonton, Canada, was founded by Dr. Mikolaj Raszek, founder and managing director of Merogenomics, is one scientist who discussed the seriousness of these findings. ![]()
0 Comments
Leave a Reply. |